CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jan. 4, 2019– Epizyme, Inc. (Nasdaq: EPZM), a clinical-stage company developing novel epigenetic therapies, today announced a comprehensive set of pipeline updates, including […]
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jan. 4, 2019– Epizyme, Inc. (Nasdaq: EPZM), a clinical-stage company developing novel epigenetic therapies, today announced a comprehensive set of pipeline updates, including […]